Storia in 1 fonti

Roche signs trispecific T cell engager pact with Simcere in another China deal

Roche licenses Simcere Zaiming's preclinical trispecific T cell engager SIM0660 for $75M upfront, up to $1.53B in biobucks, its second China biotech deal this month.

Raccontata da

endpoints.news

Timeline cronologica

martedì 1 settembre 2026·endpoints.news
Roche signs trispecific T cell engager pact with Simcere in another China deal
Roche licenses Simcere Zaiming's preclinical trispecific T cell engager SIM0660 for $75M upfront, up to $1.53B in biobucks, its second China biotech deal this month.